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Transapical Aortic Valve Implantation
Incidence and Predictors of Paravalvular Leakage
and Transvalvular Regurgitation in a Series of 358 Patients
Axel Unbehaun, MD, Miralem Pasic, MD, PHD, Stephan Dreysse, MD, Thorsten Drews, MD,
Marian Kukucka, MD, Alexander Mladenow, MD, Ekaterina Ivanitskaja-Kühn, MD,
Roland Hetzer, MD, PHD, Semih Buz, MD
Berlin, Germany
Objectives The aim of this study was to evaluate the results when the surgical concept of not accepting intraprocedural
paravalvular leakage was applied for transcatheter aortic valve implantation (TAVI).
Background The surgical strategy of conventional aortic valve replacement does not accept paraprosthetic leakage and re-
quires immediate action to eliminate it. However, paravalvular leakage is the major concern after TAVI.
Methods A total of 358 patients underwent transapical TAVI with balloon-expandable prostheses. The modified procedural
strategy consisted of precise positioning of the prosthesis using a modified TAVI technique and immediate addi-
tional intraprocedural treatment to eliminate relevant paravalvular leakage.
Results Balloon redilation of the transcatheter valve was performed in 18 patients (5%), and additional second valves
were implanted in 13 (4%). At the end of the procedure, 186 patients (52%) had no paravalvular or transvalvular
regurgitation. In the remaining 172 patients, paravalvular leakage was observed in 113 (32%), transvalvular
leakage in 47 (13%), and both in 12 (3%). Leakage was trace in 88 patients (25%), mild in 82 (23%), and mod-
erate in 2 (0.6%). Multivariate analysis identified male sex, New York Heart Association functional class IV, and
no previous aortic valve replacement as predictors of post-procedural leakage. Cumulative survival was not de-
pendent on post-procedural regurgitation rate. Overall mortality was 5  1% at 30 days, 14  2% at 6 months,
17  2% at 1 year, and 33  4% at 2 years.
Conclusions The modified procedural strategy of transapical TAVI with a balloon-expandable prosthesis was associated with a
low incidence of relevant prosthetic regurgitation. (J Am Coll Cardiol 2012;59:211–21) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.857p
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lSurvival in patients with severe aortic stenosis who cannot
undergo surgery has been improved by transcatheter aortic
valve implantation (TAVI) (1–3). The early results are
encouraging, with reported 30-day mortality rates below
10% and 1-year survival rates above 70% at experienced
centers (3–9).
Standard surgical policy accepts only trace paravalvular
leakage after conventional aortic valve replacement. Mod-
erate to severe prosthetic dysfunction is a clear indication for
immediate revision (10). Even in the era of very sensitive
echocardiography, the rate of trace and mild paraprosthetic
regurgitation after conventional surgery is clearly below 20%
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accepted October 3, 2011.(11). Contrary to these standard surgical policies, parapros-
thetic leakage is observed and accepted in the majority of
TAVI patients. The reported rates of moderate or severe
regurgitation vary between 10% (3,4) and up to 20% or more
in larger series (8,12–14), regardless of the type of prostheses.
A negative influence of significant paraprosthetic leakage on
survival has recently been demonstrated (8). Although only
rocedural complications are strongly associated with early
ortality, post-procedural moderate or severe regurgitation
ainly affects late outcomes (8). However, influence of proce-
ural technique, incidence, and predictors of paravalvular
egurgitation are not yet clearly defined.
We adopted the “surgical way of thinking” and decided to
ccept only trivial or mild paraprosthetic regurgitation after
AVI (9). Our institutional procedural policy consisted of a
odified TAVI strategy. It included a modified implantation
echnique (15) that reduces the incidence and severity of
eakage and immediate treatment of higher grade parapros-
hetic regurgitation by additional balloon redilation and, if
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of a second prosthesis (9,16).
Here we report our institu-
tional experience with how to
manage, avoid, and anticipate re-
gurgitation in transapical TAVI
using balloon-expandable trans-
catheter valves.
Methods
Patients. Between April 2008
and March 2011, 358 consecu-
tive patients (mean age 80  8 years; range: 29 to 99 years)
with severe aortic stenosis underwent transapical TAVI.
There were 120 men (34%) and 238 women (66%). The
Abbreviations
and Acronyms
HU  Hounsfield units
LVOT  left ventricular
outflow tract
MSCT  multislice
computed tomography
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiography
Pre-Procedural Parameters of Patient Group asDivided Into Subg oups Taking Into Account PoTable 1 Pre-P cedur l Param ters f PatieDivided Into Subgroups Taking Into
Parameter
All Patients
(n  358)
N
Age (yrs) 79.5 8.3
Men 120 (34%)
BMI (kg/m2) 27.1 5.4
EuroSCORE (%) 38.2 20.7
STS score (%) 18.7 15.7
NT-proBNP (pg/ml) 5,352 8,413
NYHA functional class IV 110 (31%)
Cardiogenic shock 21 (6%)
COPD 170 (47%)
FEV1 (%) 74.8 23.0
SPAP  50 mm Hg 137 (38%)
Creatinine (mg/dl) 1.2 0.6
Renal failure 82 (23%)
Diabetes mellitus 89 (25%)
Coronary artery disease 211 (59%)
Atrial fibrillation 110 (31%)
Cerebral ischemic lesion 87 (24%)
Peripheral artery disease 252 (70%)
Severely calcified ascending aorta 54 (15%)
Previous pacemaker/ICD 36 (10%)
Previous AVR 19 (5%)
Previous CABG 59 (16%)
Previous MVR 9 (3%)
LVEF (%) 50.0 14.2
LVEF  35% 74 (21%)
LVEDD (mm) 49.0 7.6
dP mean (mm Hg) 48.3 14.7
AVA (cm2) 0.67 0.17
Annulus, TEE (mm) 22.0 1.5
Annulus, CT (mm) 23.1 2.3
Aortic regurgitation (grade II–IV) 46 (13%)
Mitral regurgitation (grade III or IV) 22 (6%)
Tricuspid regurgitation (grade III or IV) 14 (4%)
Values are mean  SD or n (%).
AVA  aortic valve area; AVR  aortic valve replacement; BMI  b
obstructive pulmonary disease; CT  computed tomography; dP mean
Operative Risk Evaluation; FEV1  forced expiratory volume in 1 sec
end-diastolic diameter; LVEF  left ventricular ejection fraction; MVR
natriuretic peptide; NYHA  New York Heart Association; SPAP  systolic pu
transesophageal echocardiography.mean logistic European System for Cardiac Operative Risk
Evaluation score for the whole group was 38  21% (range:
4% to 97%), and the mean Society of Thoracic Surgeons
score was 19  16% (range: 1% to 90%). The preoperative
patients’ characteristics are given in Table 1. The median
follow-up period was 331 days (interquartile range: 113 to
585 days), with a total of 358 patient-years of follow-up.
The follow-up for this prospective study was 100%. All
patients or their representatives gave informed consent. The
study was approved by our institutional review board.
Inclusion and exclusion criteria. The risk for conventional
aortic valve replacement was evaluated by the heart team. In
general, high-risk patients with severe aortic stenosis were
considered for TAVI if the logistic European System for
Cardiac Operative Risk Evaluation score was at least 20% or
ole andc dural Regurgitationup as a Whole and
unt Post-Procedural Regurgitation
urgitation
186)
Regurgitation of Any Kind
(n  172) Range
 8.5 79.8 8.0 29–99
(28%) 68 (40%) —
 5.7 26.6 5.1 17–59
 19.2 39.3 22.1 4–97
 13.4 19.6 17.9 1–90
 6,440 5,953 9,984 10,000–77,000
(26%) 62 (36%) —
(5%) 12 (7%) —
(45%) 86 (50%) —
 22.0 75.8 24.0 13–145
(34%) 73 (42%) —
 0.7 1.2 0.6 0.5–6.3
(24%) 38 (22%) —
(26%) 41 (24%) —
(58%) 103 (60%) —
(32%) 51 (30%) —
(25%) 41 (24%) —
(69%) 124 (72%) —
(18%) 20 (12%) —
(9%) 19 (11%) —
(9%) 2 (1%) —
(16%) 30 (17%) —
(2%) 5 (3%) —
 13.8 50.4 14.7 10–70
(23%) 32 (19%) —
 7.6 48.7 7.6 32–80
 14.5 49.6 14.8 8–100
 0.18 0.66 0.17 0.3–1.8
 1.5 22.2 1.5 17–25
 1.9 23.3 2.7 17–31
(12%) 23 (13%) —
(8%) 8 (5%) —
(3%) 8 (5%) —
ass index; CABG  coronary artery bypass grafting; COPD  chronic
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Patients with lower risk scores were accepted for TAVI only
if there were specific reasons (e.g., “porcelain aorta”). In
accordance with our institutional “no exclusion” policy, no
patient was excluded regardless of a very high risk profile,
poor left ventricular performance, or even the presence of
cardiogenic shock (9). The only exclusion criteria were the
presence of endocarditis or too large a native aortic annulus
of above 24 mm (7 patients with aortic annuli of 25 mm
were also accepted for specific reasons). Concomitant cor-
onary artery disease was not considered a contraindication to
TAVI but was treated simultaneously according to our
institutional policy (9).
Prerequisites and implantation technique. All procedures
were performed under general anesthesia in the special
hybrid suite with a monoplane angiographic system (Sie-
mens Artis zee, Siemens AG, Munich, Germany). A
consistent heart team of cardiac surgeons, cardiologists, and
anesthesiologists performed all valve interventions.
Transapical aortic valve implantation was performed in all
patients through a mini left anterior thoracotomy with a
balloon-expandable transcatheter stent prosthetic xenograft
valve (Edwards Sapien THV, Edwards Lifesciences, Irvine,
California). The principal surgical technique, as described in
detail by Walther et al. (17), was used with several modifi-
cations (15). Simultaneous angiographic monitoring was
applied during slow and gradual inflation of the balloon
instead of fast and immediate inflation, as originally de-
scribed (17). This enabled very precise positioning of the
valve at a higher position than usual, which reduced the
incidence of paravalvular leakage (9,16). Special attention
was paid to achieve a higher valve position if there were
subvalvular calcified masses in the left ventricular outflow
tract (LVOT).
Measurement of annular diameter and valve selection.
The annulus was measured pre-operatively using transtho-
racic echocardiography (parasternal long-axis view) in all
patients. Additionally, in 307 patients (86%), we performed
annular measurements using multislice computed tomogra-
phy (MSCT) that influenced valve size selection in border-
line cases. In 51 patients (14%), we abandoned MSCT for
clinical reasons (urgency, hemodynamic instability, renal
failure). The definitive measurements were performed again
in the operating room before the intervention using trans-
esophageal echocardiography (TEE) (midesophageal short-
axis view and long-axis view at midsystole). Standard TEE
also included assessment of the diameters of the LVOT,
sinus of Valsalva, sinotubular junction, and ascending aorta.
Specific pathologies influencing the procedure and guiding the
desired position of the prosthesis, such as localized calcified
masses, were identified. A valve size of 23 mm was chosen for
aortic valve annuli smaller than 21 mm and a 26-mm prosthe-
sis for annular diameter of 21 mm or larger (16).
Intraprocedural policy with regard to paraprosthetic
leakage. In accordance with our institutional procedural
policies (9), only trivial or mild paraprosthetic regurgitationwas accepted after TAVI. If higher grade regurgitation was
present, immediate treatment was performed, applying bal-
loon redilation (with additional 1 to 3 ml) of the implanted
transcatheter valve and, if necessary, implantation of a
second prosthesis of the same size (9,16).
Determination of regurgitation. The occurrence of para-
prosthetic and transvalvular regurgitation was always evalu-
ated using TEE and angiography in all patients. For
assessment with TEE, long-axis and short-axis views were
used. A first assessment with TEE was performed imme-
diately after the valve was deployed. While the stiff guide-
wire was still in place, a rough grading of regurgitation was
performed by means of color Doppler flow echocardiogra-
phy. In the presence of relevant regurgitation, additional
acts were performed (as described earlier). If there was no
relevant paravalvular or valvular regurgitation, the stiff
guidewire was removed and the procedure was finished.
Regurgitation was further evaluated using contrast echocar-
diography with agitated succinylated gelatin (Gelafundin
4%, B. Braun Melsungen AG, Melsungen, Germany) after
the sheath and guidewire were removed from the heart.
Aortic root angiography with 20 ml iopromide (Ultravist-
370, Bayer AG, Leverkusen, Germany) was performed in all
patients. The severity of regurgitation was qualitatively
assessed (10,18) and precisely graded using TEE according
to the guidelines (10,19). The width and height of regur-
gitation jets as well as “jet anatomy” (20) were assessed in
color Doppler flow. Aortic regurgitation was categorized
according to the localization as paravalvular, transvalvular,
or combined paravalvular and transvalvular regurgitation.
Overall aortic regurgitation was classified as absent (0), trace
(I), mild (I), moderate (II), and severe (III or IV) (10,19).
Post-procedural assessment using TEE and angiography
was made uniformly under stable hemodynamic conditions
in all patients, with a mean arterial blood pressure of 70 mm
Hg and a mean heart rate of 90 beats/min.
Assessment of aortic valve morphology by MSCT. Ret-
rospective analysis of MSCT was performed in all patients
who needed another valve intervention to minimize intra-
procedural regurgitation as well as in all patients with
post-procedural regurgitation of more than grade I. A
control group of matched patients without any post-
procedural regurgitation and without any further intrapro-
cedural valve intervention was generated. Matching was
done according to congruence in general patient parameters
that were found to be predictive for regurgitation in
univariate analysis (sex, absence or presence of previous
aortic valve replacement, TEE-measured annular diam-
eter, and New York Heart Association functional class).
The amount of calcification in the device landing zone
(consisting of the aortic annulus, valvular cusps, and
LVOT) was assessed semiquantitatively by visual estima-
tion (grade 0 to IV) (21). The shape of the aortic annulus
was classified as oval when 2 orthogonal diameters
differed by more than 25%; otherwise, it was classified as
round. The number of open or fused commissures was
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score (22) was calculated and applied to quantify the
degree of calcification of the device landing zone (21).
The cutoff level to detect calcium was set between 450
and 600 Hounsfield units (HU). Standard calcium scor-
ing software was used (syngo, Siemens AG).
Statistical analysis. Continuous variables are expressed as
mean SD and as maximal and minimal absolute numbers.
Statistical analyses of post-operative changes in echocardio-
graphic parameters were carried out using paired t tests. The
Kaplan-Meier survival functions for subgroups with and
without post-procedural regurgitation were calculated. A
Gehan test was used to analyze differences between survival
functions. Logistic regression was used to identify possible
risk factors for post-procedural regurgitation. First, a uni-
variate approach for all possible risk factors was evaluated.
In the second step, several risk factors were combined in
multivariate logistic regression models. The best model was
chosen according to the Akaike information criterion.
Accordingly, multislice computed tomographic parameters
from the regurgitation group and the matched control group
Figure 1 Effect of Intraprocedural Reintervention to Minimize R
Intraprocedural grade of regurgitation (left) in all 21 patients (from top to bottom
and/or implantation of a second prosthesis before reintervention and final grade owere analyzed using univariate and multivariate logistic
regression statistics. Data were evaluated using IBM SPSS
version 19 (IBM, Armonk, New York). A p value 0.05
was considered significant.
Results
Intraprocedural TAVI course. Technical success of valve
implantation was 99%, with conversion to conventional
surgery because of annulus rupture in 2 patients (0.6%).
There was no conversion to conventional surgery because of
regurgitation, prosthesis migration, or aortic dissection. A
23-mm prosthesis was used in 124 patients (35%) and a
26-mm prosthesis in 234 (65%).
Moderate or severe regurgitation requiring additional
intraprocedural intervention. The rate of moderate or
severe regurgitation (paraprosthetic and/or central) after
primary implantation was 6% (23 of 358 patients). Addi-
tional redilation (with additional 1 to 3 ml) of the primarily
implanted valve was performed in 18 patients (5%) (Fig. 1).
Additional valves of the same size were implanted in 13
gitation
nological order) who underwent additional redilation
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prostheses were implanted in 5 patients and second 26-mm
prostheses in 8 patients. Two patients (0.6%) with moderate
regurgitation (grade II) had intraprocedural bleeding near
the apically placed introducer (because of very fragile myo-
cardium) during primary valve implantation, and the apex
was safely closed without intention to treat moderate regur-
gitation (which would have jeopardized the TAVI proce-
dure). The reintervention rate dropped from 8% in first 100
patients to 3% in the last 58 patients. All procedural
parameters are given in Table 2.
Transvalvular regurgitation. The occurrence of severe
transvalvular regurgitation related to lacking or restricted
leaflet movements was observed in 6 patients (2%). Tenta-
tive manipulations with the pigtail catheter successfully
eliminated aortic regurgitation in 3 patients (0.8%). Addi-
tional prostheses of the same size were implanted in 3
patients (0.8%), reducing aortic regurgitation from grade III
(severe) to grade I (mild) in 1 patient and eliminating
regurgitation completely in the other 2 patients.
Paraprosthetic regurgitation. Significant paraprosthetic
regurgitation with or without transvalvular regurgitation
occurred more frequently than transvalvular. Redilation
without implanting a second valve (Fig. 2) was performed in
8 patients (2%), reducing aortic regurgitation from grade I
to II (mild) in 1 patient, grade I (mild) in 4 patients, and
grade I (trace) in 1 patient and eliminating regurgitation
(grade 0) in 2 patients. Redilation followed by the implan-
tation of a second prosthesis was performed in 10 patients
(3%). At the end of the procedure, regurgitation was
reduced to grade I to II (mild) in 1 patient, grade I (mild)
in 2 patients, and grade I (trace) in 3 patients, and
regurgitation was eliminated in 4 patients.
Complications after additional intraprocedural intervention.
The rate of complications, problems, and the way we
managed them in the first 194 patients have recently been
reported (16). In all 21 patients who underwent redilation
and/or the implantation of a second prosthesis, there was no
annular rupture, aortic dissection, or coronary ostia occlu-
Intraprocedural Parameters of Patient Group as a Whole andDivided Into Subgroups Taking In o Account Post-Procedural RegurTable 2 Intrap ocedural Param ters f Patient Gr up as a WhoDivided Into Subgroups Taking Into Account Post-Proc
Parameter
All Patients
(N  358)
Contrast medium (ml) 111 63
Radiation time (min) 9.4 6.4
Dose-area product (Gy · m2) 7,764 5,899
26-mm prosthesis 234 (65%)
dP mean (mm Hg) 4.8 2.5
Simultaneous PCI 39 (11%)
Use of CPB 27 (8%)
Redilation 18 (5%)
Second prosthesis 13 (4%)
Values are mean  SD or n (%). *Statistically significant (p  0.05).
CPB  cardiopulmonary bypass; dP mean  mean transvalvular gradient; PCI  percutaneoussion. One patient developed acute pulmonary edema related sto severe transvalvular aortic regurgitation after initial valve
deployment. Immediate implantation of a second prosthesis
was performed under emergency femoro-femoral cardiopul-
monary bypass. To achieve pulmonary recovery, the patient
received extracorporeal membrane oxygenation support for
24 h. After initial recovery, the patient developed sepsis and
multiple-organ failure. Within this subgroup of 21 patients,
there were 3 in-hospital deaths related to septic multiple-
organ failure in 2 patients and lack of myocardial recovery
in 1 patient. Surgical revision for bleeding was necessary
in 1 patient. The implantation of a permanent pacemaker
was required in 2 of 21 patients. Weaning from the
respirator was prolonged in 3 of 21 patients who under-
went tracheostomy during further follow-up. There were
no neurological deficits in the postoperative courses of
these 21 patients.
Grade of regurgitation at the end of the TAVI procedure. At
the end of the TAVI procedure, no regurgitation was
observed in 186 patients (52%), and 172 patients (48%) had
some regurgitation. The grades of regurgitation were trace
in 88 patients (24% of all 358 patients), mild in 82 (23%),
and moderate in 2 (0.6%). There was no severe (II)
regurgitation (Fig. 3).
With regard to the group of 172 patients with any
regurgitation, it was trace in 51% of these patients, mild in
48%, and moderate in 1%. Regurgitation was paravalvular in
32% (113 of 358 patients), transvalvular in 13% (47 of 358),
and combined paravalvular and transvalvular in 3% (12 of
358). In the 172 patients with regurgitation, it was paraval-
vular, transvalvular, and combined in 66%, 27%, and 7%,
respectively.
Further findings on TEE. The mean transvalvular gradi-
ent was significantly (p  0.001) reduced from 48.3  14.7
m Hg (range: 8 to 100 mm Hg) to 4.8  2.4 mm Hg
(range: 1 to 20 mm Hg). The aortic valve area increased
significantly (p  0.001) from 0.7  0.2 cm2 (range: 0.3 to
1.8 cm2) to 2.1  0.5 cm2 (range: 0.9 to 3.5 cm2).
eneral predictors of regurgitation. Predictors of post-
rocedural regurgitation of any kind with statistical
iond
l Regurgitation
gurgitation
 186)
Regurgitation of Any Kind
(n  172) p Value
 53 118 72 0.061
 5.4 9.8 7.3 0.235
 3,934 8,476 7,351 0.031*
5 (67%) 109 (63%) 0.505
 2.3 5.1 2.6 0.072
1 (11%) 18 (11%) 0.866
1 (6%) 16 (9%) 0.237
6 (3%) 12 (7%) 0.146
6 (3%) 7 (4%) 0.780
ry intervention.gitatle n
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1ignificance in univariate analysis (Table 3) were male
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previous aortic valve replacement, and annular size (on
TEE). There was a weak correlation (r  0.260) between
annular size measurements on TEE and MSCT. By
Figure 3 Final Grade of Regurgitation
Distribution of regurgitation at the end of the transcatheter aortic valve implantatio
Figure 2 Asymmetric Distribution of Calcification Within Aortic
Paravalvular regurgitation was reduced by redilation. (A) Different multislice compu
the noncoronary cusp. (B) Short-axis and long-axis transesophageal echocardiogra
ment (middle), and after redilation (right). The jet at the left noncoronary commis
reduced (yellow arrow).multivariate analysis, the absence of previous aortic valve
replacement, male sex, and New York Heart Association
functional class IV were the strongest predictors of
post-procedural regurgitation (Table 4).
edure is given, taking into account grade and location of leakage.
e Cusps Indicating Risk for Post-Procedural Leakage
mographic views and schematic drawings indicating severe calcification (red) of
iews before transcatheter aortic valve implantation (left), after prosthesis deploy-
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Retrospective detailed analysis of preoperatively performed
MSCT was performed in 78 patients (22%). Within the
regurgitation subgroup of 39 patients (11%), there were 15
(38% of 39) with oval-shaped annuli, 13 (33%) with severe
calcification of the LVOT (grade III or IV) (Fig. 4), 26
(67%) with severe calcification of the cusps (grade III or IV),
29 (74%) with asymmetric distribution of calcium within
the cusps, and 29 (74%) with 2 or 3 nonfused commissures.
There were 22 patients (56%) with severely calcified device
landing zones. The mean Agatston calcium scores were
1,363  766 HU (range: 66 to 3,181 HU) in the
regurgitation subgroup and 986  586 HU (range: 48 to
2,993 HU) in the matched control group. In univariate
analysis, Agatston calcium score was found to be a
significant predictor of intraprocedural regurgitation
Predictive Factors of Post-Procedural Regurgitation(R sul s of Univariate Logistic Reg ession)Table 3 Predictive Factors of Post-Procedural Regurgitation(Results of Univariate Logistic Regression)
Parameter
Odds
Ratio
95% Confidence
Interval p Value
Age 1.01 0.98–1.03 0.444
Male 1.66 1.06–2.58 0.025*
BMI 0.97 0.94–1.01 0.164
EuroSCORE 1.01 1.00–1.02 0.336
STS score 1.01 0.99–1.02 0.299
NT-proBNP 1.00 1.00–1.00 0.251
NYHA functional class IV 1.58 1.04–2.42 0.033*
Cardiogenic shock 1.46 0.60–3.55 0.501
COPD 1.19 0.79–1.80 0.459
FEV1 1.00 0.99–1.01 0.449
SPAP  50 mm Hg 1.45 0.94–2.22 0.103
Creatinine 0.90 0.64–1.25 0.520
Renal failure 0.96 0.59–1.57 0.900
Diabetes mellitus 0.94 0.58–1.52 0.808
Coronary artery disease 1.10 0.72–1.68 0.669
Atrial fibrillation 0.94 0.60–1.48 0.819
Cerebral ischemic lesion 0.92 0.55–1.53 0.797
Peripheral artery disease 1.19 0.75–1.88 0.488
Severely calcified
ascending aorta
0.85 0.68–1.07 0.167
Previous pacemaker/ICD 1.12 0.61–2.43 0.602
Previous AVR 0.12 0.03–0.51 0.001*
Previous CABG 1.13 0.65–1.97 0.776
Previous MVR 1.35 0.36–5.10 0.744
LVEF 1.00 0.99–1.02 0.634
LVEDD 0.99 0.96–1.02 0.444
dP mean 1.01 1.00–1.03 0.115
Annulus, TEE 1.18 1.03–1.37 0.020*
Annulus, CT 1.07 0.97–1.18 0.186
Aortic regurgitation
(grade II–IV)
1.08 0.58–2.01 0.875
Mitral regurgitation
(grade III or IV)
0.35 0.07–1.75 0.286
Tricuspid regurgitation
(grade III or IV)
0.64 0.15–2.70 0.725
*Statistically significant (P  0.05).
Abbreviations as in Table 1.(odds ratio per 100 units: 1.09; 95% confidence interval:1.01 to 1.17; p  0.029). Results from the multivariate
analysis are given in Table 5. A schematic overview of
morphological risk factors for post-procedural regurgita-
tion is given in Figure 5.
Survival. There was no statistically significant difference
(p  0.771) in survival between patients without intrapro-
cedural regurgitation and patients with trace or mild regur-
gitation. The observed 1-year survival rates were 83 3% in
atients without regurgitation, 85  4% in patients with
trace regurgitation, and 83  5% in patients with mild
egurgitation. The 2-year survival rates in patients without
egurgitation and in those with trace and mild regurgitation
ere 66  6%, 72  8%, and 67  7%, respectively. All
aplan-Meier survival functions are given in Figure 6.
ater aortic valve interventions. During the follow-up of
ll 358 patients, 3 patients underwent conventional aortic
alve replacement (endocarditis in 2 patients, progression
rom mild to severe paravalvular regurgitation in 1 patient).
nother patient underwent a second TAVI procedure
new-onset severe transvalvular regurgitation). The overall
ate of later aortic valve interventions was 1%.
iscussion
ccurrence of leakage after TAVI versus conventional
ortic valve replacement. Our reported strategy consists of
modified TAVI technique in combination with immediate
ntraprocedural treatment of relevant paravalvular (or trans-
alvular) regurgitation resulting in a very low regurgitation
ate. Although TAVI procedures are imperfect compared
ith precise surgical valve replacement with regard to the
ccurrence of paraprosthetic regurgitation, the modified
AVI strategy reaches the results of conventional aortic
alve replacement. At the end of the procedure, moderate
egurgitation was observed in only 2 patients and was
ccepted as an exception. The majority of our patients (52%)
ad no regurgitation at the end of the TAVI procedures.
race paravalvular regurgitation is associated with benign
rognoses in the majority of surgically treated patients (11).
ransferring this finding to our TAVI group, trace or mild
egurgitation seems to be acceptable in these high-risk
atients. During the follow-up, 1% of our patients needed
dditional aortic valve replacements because of endocarditis
0.6%) or progression of regurgitation (0.6%). The midterm
ollow-up results are comparable with those of surgically
mplanted bioprosthetic valves (11).
Predictive Factors of Post-Procedural Regurgitation(Results of Multivariate Logistic ression)Table 4 Pred ctive Fact rs of Post-Procedural Regurgitation(Results of Multivariate Logistic Regression)
Parameter
Odds
Ratio
95% Confidence
Interval p Value
Sex 1.96 1.23–3.12 0.005*
NYHA functional
class IV
1.71 1.08–2.73 0.023*
Previous AVR 0.08 0.02–0.38 0.001**Statistically significant (p  0.05).
Abbreviations as in Table 1.
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survival rate up to 85% and a 2-year survival rate up to 72%,
are a continuation of our previous encouraging reports
(9,16,23). Contrary to the report by Tamburino et al. (8),
our reported modified TAVI strategy achieved a lower rate
of leakage and had no impact on midterm survival. This is
the most important benefit of the modified strategy to avoid
regurgitation during TAVI (9).
Regurgitation after TAVI with balloon-expandable versus
self-expandable valves. Only a few previous studies ana-
lyzed local predictive factors for regurgitation in a limited
Figure 4 Calcification of the LVOT Indicating Risk for Post-Proc
Post-procedural regurgitation was preoperatively anticipated and minimized by a hi
esophageal echocardiography (right) indicating a severely calcified rim (red arrow
cally in a high position (3/4 above the annulus). There was mild regurgitation on a
Predictive Morphological Factors(Parameters From Multislice ComputedTomography) of Significant Intraproc uraland/or Post-P cedural RegurgitationR sul s f Multivariate Lo is ic Regression)
Table 5
Predictive Morphological Factors
(Parameters From Multislice Computed
Tomography) of Significant Intraprocedural
and/or Post-Procedural Regurgitation
(Results of Multivariate Logistic Regression)
Parameter
Odds
Ratio
95% Confidence
Interval p Value
Asymmetric cusp
calcification
5.65 0.44–3.03 0.009*
Device landing zone
calcification
4.90 0.79–2.39 0.001*
Oval-shaped annulus 9.16 0.68–3.75 0.005**Statistically significant (p  0.05).number of inhomogenous TAVI cohorts. Détaint et al. (24)
focused on annular size in 28 and 46 patients treated with
transapical and transfemoral implantation, respectively, of
the Edwards Sapien valve, with a rate of 17% for moderate
or severe regurgitation. They introduced a cover index and
found prosthesis-annulus incongruence to be a predictor of
regurgitation. Our clinical observations support the findings
that the degree of oversizing of the balloon-expandable
valve prosthesis is inversely related to the risk for paraval-
vular regurgitation. This might explain why regurgitation
occurs more often in tall men than in smaller women. More
precise methods of the assessment of the diameter of the
native annulus are necessary. Further improvements to the
prosthesis itself without increasing the risk for annular
rupture need to be made.
It also seems that paravalvular leakage might be less
frequent after implantation of balloon-expandable valves in
comparison with self-expandable valves. Sherif et al. (25)
analyzed regurgitation in 50 patients treated with transfemo-
ral implantation of the self-expanding Medtronic Core-
Valve prosthesis (Medtronic, Inc., Minneapolis, Minne-
sota), with a rate of 40% for regurgitation of grades II and
al Leakage
osition of the prosthesis. (A) Angiography, schematic drawing (left), and trans-
e left ventricular outflow tract (LVOT). (B) The prosthesis was implanted specifi-
aphy (blue arrows) and on transesophageal echocardiography.edur
gher p
s) in th
ngiogrIII. An increasing LVOT-aorta angle as well as increasing
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was associated with a higher likelihood of paravalvular
regurgitation. In agreement with a report on the self-
expanding Medtronic CoreValve prosthesis (21), we ob-
served severe calcification in the device landing zone as a
morphological cause of paraprosthetic regurgitation in our
group.
Predictive factors for regurgitation. The presence of a
degenerated bioprosthesis was clearly associated with a very
Figure 5 Schematic Drawings Indicating Morphological Risk Fa
The anticipated occurrence of leakage is marked (arrow). Nonfused commissures
masses (red) within the cusps (middle), and calcified structures in the left ventric
coronary cusp; NCC  noncoronary cusp; RCC  right coronary cusp.
Figure 6 Midterm Survival After Transcatheter Aortic Valve Imp
Kaplan-Meier survival functions of all patients without cardiogenic shock divided in
trace regurgitation (blue), and mild regurgitation (red).low risk for regurgitation. It indicates that the “valve-in-
valve” concept is a safe procedure avoiding repeat sternot-
omy and providing good performance of the prosthesis (23).
Male gender, signs of advanced heart failure, and larger
annuli were found to be predictive of regurgitation. Most
likely, the annular size was sex related. It indicates that
larger annuli in male patients are related to an increased risk
for regurgitation or even that the annular diameter was
underestimated. Our results are in contrast to those from
for Post-Procedural Regurgitation
neighborhood of bulky masses (left), an asymmetric distribution of calcified
tflow tract (LVOT) (right) are anatomical regurgitation substrates. LCC  left
tion
roups are given: no regurgitation (black),ctors
in the
ular oulanta
to 3 g
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body surface area was among the strongest predictors of
paravalvular regurgitation (11). In conclusion, morphologi-
cal factors of the aortic valve and its environment seem to be
much more important for paravalvular regurgitation than
general parameters.
How to minimize or avoid paravalvular regurgitation.
The risk for postprocedural paravalvular regurgitation can
be anticipated from pre-operative MSCT and TEE. We
agree with others that MSCT provides helpful additional
information (21,26). The following morphological constel-
lations are associated with a higher risk for regurgitation:
asymmetrically calcified cusps, especially in combination
with a large annular size or an oval annular shape; nonfused
commissures in the neighborhood of calcified masses; and
the presence of LVOT calcification.
The main reason for our low post-procedural regurgita-
tion rate is our modified implantation technique, which has
been described elsewhere (15). Any uncertainty regarding
the desired valve position must be avoided. Furthermore, we
were able to implant the valve at a higher position, which we
found to be very effective to prevent regurgitation. Angio-
graphic monitoring preserves from obstructions of the
coronary ostia, which were rare in our cohort (16).
Redilation with or without the implantation of a second
valve is a suitable option if paravalvular regurgitation is
observed after TAVI. Both options were rarely necessary in
our group of patients but were found to be very effective. If
severe transvalvular regurgitation occurs, it is worth trying
manipulation with the pigtail catheter to mobilize a non-
moving leaflet first. Then, if necessary, the implantation of
a second valve will eliminate it definitively.
Study limitations. We exclusively used 23-mm and
26-mm devices, because the 29-mm prosthesis only recently
became commercially available. Another limitation of the
study is the relatively short follow-up period of up to 35
months. The risk for early valve degeneration, the proba-
bility of progressive regurgitation, and the rate of endocar-
ditis need to be assessed over a longer period, and therefore,
long-term follow-up is needed.
Conclusions
TAVI procedures need to achieve the results obtained with
surgical valve replacement. Until this has been accom-
plished, an anticipated high risk for regurgitation should
influence the decision-making process of whether a patient
with aortic stenosis should undergo TAVI or conventional
surgery. Our initial experience with modified transapical
approach in 358 patients demonstrates that a low rate of
paravalvular regurgitation after TAVI can be achieved.
Acknowledgments
Other members of the TAVI team are Giuseppe D’Ancona,
MD, PhD, Christoph Klein, MD, and Katrin Schäfer. The
authors are grateful to Natalia Solowjowa, MD, for per-forming computed tomographic scans and obligingly pro-
viding support in computed tomographic analysis. The
authors thank Julia Stein for statistical analyses, Anne Gale
for editorial assistance and Rosemarie Günther for secre-
tarial support.
Reprint requests and correspondence: Prof. Miralem Pasic,
Deutsches Herzzentrum Berlin, Augustenburger Platz 1, D-13353
Berlin, Germany. E-mail: pasic@dhzb.de.
REFERENCES
1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter
implantation of an aortic valve prosthesis for calcific aortic stenosis:
first human case description. Circulation 2002;106:3006–8.
2. Lichtenstein SV, Cheung A, Ye J, et al. Transapical transcatheter
aortic valve implantation in humans: initial clinical experience. Circu-
lation 2006;114:591–6.
3. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve
implantation for aortic stenosis in patients who cannot undergo
surgery. N Engl J Med 2010;363:1597–607.
4. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical
aortic-valve replacement in high-risk patients. N Engl J Med 2011;
364:2187–98.
5. Bleiziffer S, Ruge H, Mazzitelli D, et al. Survival after transapical and
transfemoral aortic valve implantation: talking about two different
patient populations. J Thorac Cardiovasc Surg 2009;138:1073–80.
6. Walther T, Schuler G, Borger MA, et al. Transapical aortic valve
implantation in 100 consecutive patients: comparison to propensity-
matched conventional aortic valve replacement. Eur Heart J 2010;31:
1398–403.
7. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve
implantation for the treatment of severe symptomatic aortic stenosis in
patients at very high or prohibitive surgical risk: acute and late
outcomes of the multicenter Canadian experience. J Am Coll Cardiol
2010;55:1080–90.
8. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and
predictors of early and late mortality after transcatheter aortic valve
implantation in 663 patients with severe aortic stenosis. Circulation
2011;123:299–308.
9. Pasic M, Unbehaun A, Dreysse S, et al. Transapical aortic valve
implantation in 175 consecutive patients, excellent outcome in very
high-risk patients. J Am Coll Cardiol 2010;56:813–20.
10. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines
for the management of patients with valvular heart disease: a report of
the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Writing Committee to Revise the
1998 Guidelines for the Management of Patients With Valvular Heart
Disease). J Am Coll Cardiol 2006;48:e1–148.
11. O’Rourke DJ, Palac RT, Malenka DJ, Marrin CA, Arbuckle BE,
Plehn JF. Outcome of mild periprosthetic regurgitation detected by
intraoperative transesophageal echocardiography. J Am Coll Cardiol
2001;38:163–6.
12. Zahn R, Gerckens U, Grube E, et al. Transcatheter aortic valve
implantation: first results from a multi-centre real-world registry. Eur
Heart J 2011;32:198–204.
13. Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve
implantation: impact on clinical and valve-related outcomes. Circula-
tion 2009;119:3009–16.
14. Abdel-Wahab M, Zahn R, Horack M, et al. Aortic regurgitation after
transcatheter aortic valve implantation: incidence and early outcome.
Results from the German transcatheter aortic valve interventions
registry. Heart 2011;97:899–906.
15. Pasic M, Dreysse S, Drews T, et al. Improved technique of transapical
aortic valve implantation: “the Berlin addition.” Ann Thorac Surg
2010;89:2058–60.
16. Pasic M, Buz S, Dreysse S, et al. Transapical aortic valve implantation
in 194 patients: problems, complications, and solutions. Ann Thorac
Surg 2010;90:1463–70.
17. Walther T, Dewey T, Borger MA, et al. Transapical aortic valve
implantation: step by step. Ann Thorac Surg 2009;87:276–83.
22
2
2
2
221JACC Vol. 59, No. 3, 2012 Unbehaun et al.
January 17, 2012:211–21 Leaks After Transapical Aortic Valve Implantation18. Sellers RD, Levy MJ, Amplatz K, Lillehei CW. Left retrograde
cardioangiography in acquired cardiac disease: technic, indications and
interpretations in 700 cases. Am J Cardiol 1964;14:437–47.
19. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for
evaluation of prosthetic valves with echocardiography and Doppler
ultrasound: a report from the American Society of Echocardiography’s
Guidelines and Standards Committee and the Task Force on Pros-
thetic Valves, developed in conjunction with the American College of
Cardiology Cardiovascular Imaging Committee, Cardiac Imaging
Committee of the American Heart Association, the European Asso-
ciation of Echocardiography, a registered branch of the European
Society of Cardiology, the Japanese Society of Echocardiography and
the Canadian Society of Echocardiography, endorsed by the American
College of Cardiology Foundation, American Heart Association,
European Association of Echocardiography, a registered branch of the
European Society of Cardiology, the Japanese Society of Echocardi-
ography, and Canadian Society of Echocardiography. J Am Soc
Echocardiogr 2009;22:975–1014.
20. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint
definitions for transcatheter aortic valve implantation clinical trials: a
consensus report from the valve academic research consortium. J Am
Coll Cardiol 2011;57:253–69.21. John D, Buellesfeld L, Yuecel S, et al. Correlation of device landing
zone calcification and acute procedural success in patients undergoing vtranscatheter aortic valve implantations with the self-expanding
CoreValve prosthesis. J Am Coll Cardiol Intv 2010;3:233–43.
2. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr,
Detrano R. Quantification of coronary artery calcium using ultrafast
computed tomography. J Am Coll Cardiol 1990;15:827–32.
3. Pasic M, Unbehaun A, Dreysse S, et al. Transapical aortic valve implantation
after previous aortic valve replacement: clinical proof of the “valve-in-valve”
concept. J Thorac Cardiovasc Surg 2011;142:270–7.
4. Détaint D, Lepage L, Himbert D, et al. Determinants of significant
paravalvular regurgitation after transcatheter aortic valve: implantation
impact of device and annulus discongruence. J Am Coll Cardiol Intv
2009;2:821–7.
5. Sherif MA, Abdel-Wahab M, Stöcker B, et al. Anatomic and
procedural predictors of paravalvular aortic regurgitation after implan-
tation of the Medtronic CoreValve bioprosthesis. J Am Coll Cardiol
2010;56:1623–9.
6. Tops LF, Wood DA, Delgado V, et al. Noninvasive evaluation of the
aortic root with multislice computed tomography implications for
transcatheter aortic valve replacement. J Am Coll Cardiol Img 2008;
1:321–30.Key Words: aortic regurgitation y predictors y transcatheter aortic
alve implantation.
